Rain Therapeutics Inc.
NASDAQ:RAIN
1.21 (USD) • At close January 25, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 61.4 | 40.773 | 15.367 | 7.29 |
| General & Administrative Expenses
| 15.736 | 10.739 | 3.591 | 3.538 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 |
| SG&A
| 15.736 | 10.739 | 3.591 | 3.538 |
| Other Expenses
| 0 | 0.001 | -2.022 | -0.251 |
| Operating Expenses
| 77.136 | 51.512 | 18.958 | 10.828 |
| Operating Income
| -77.136 | -51.512 | -18.958 | -10.828 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.415 | 0.12 | -2.125 | -0.074 |
| Income Before Tax
| -75.721 | -51.392 | -21.083 | -10.902 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.003 | 0.002 | -1.887 | -0.219 |
| Net Income
| -75.724 | -51.394 | -19.196 | -10.683 |
| Net Income Ratio
| 0 | 0 | 0 | 0 |
| EPS
| -2.71 | -2.65 | -1.8 | -1 |
| EPS Diluted
| -2.71 | -2.65 | -1.8 | -1 |
| EBITDA
| -77.136 | -51.392 | -20.896 | -10.842 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 |